Castle Biosciences, a provider of molecular diagnostics to improve cancer treatment decisions, today announced the Company has secured payer contracts with national provider networks MultiPlan, FedMed and Preferred Medical Claim Solutions to provide coverage of its DecisionDx assays.
These networks together provide access to more than 120 million covered lives.
"These new agreements reflect the growing clinical adoption of our portfolio of evidence-based diagnostic test services. Many more patients and their physicians can now gain critical insight into their specific tumor biology to make more informed treatment decisions," said Derek Maetzold, President and CEO of Castle Biosciences.
Castle Biosciences’ first widely adopted gene expression profile test, DecisionDx-UM, is the standard of care prognostic tool for uveal (ocular) melanoma and serves as the model for its growing lineup of practice-changing tests.
The Company’s first internally discovered and validated test, DecisionDx-Melanoma, analyzes the activity of specific genes within a cutaneous (skin) melanoma tumor to predict an individual patient’s risk of metastatic disease, independent of traditional staging modalities.
To date, the DecisionDx-Melanoma test’s accuracy has been clinically validated in three multi-center studies using over 600 archived melanoma tumor samples, with data recently published in the Journal of the American Academy of Dermatology and Clinical Cancer Research.
Castle Biosciences also offers prognostic tests in other critical areas of high unmet need, including esophageal cancer, mesothelioma and glioblastoma multiforme.